Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists

Journal of Molecular Modeling

Volumn 20, Issue 3, 2014, Pages

  Galeazzi, Roberta ^a   Massaccesi, Luca ^a   Piva, Francesco ^a   Principato, Giovanni ^a   Laudadio, Emilioano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Membrane bilayer; Molecular docking; Molecular dynamics; Serotonin

Indexed keywords

5 METHYLTHIO 1 (3 PYRIDYLCARBAMOYL) 6 (TRIFLUOROMETHYL)INDOLINE; AMOXAPINE; DULOXETINE; KETANSERIN; LOXAPINE; METHYSERGIDE; RITANSERIN; SEROTONIN; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; COMPLEX FORMATION; DRUG STRUCTURE; GENETIC VARIABILITY; LIGAND BINDING; LIPID BILAYER; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SIMULATION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84899086609     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-014-2120-0     Document Type: Article

References (86)

1. 2C receptors in the amygdala of mice. Neuropharmacology 62:474-84
2. Berg KA, Clarke WP, Cunningham KA, Spampinato U (2008) Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology 55:969-76
3. Millan MJ (2005) Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60:441-460
4. De Bodinat C, Guardiola-Lemaitre B,Mocaër E, Renard P,Muñoz C, Millan MJ (2010) Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9:628-42
5. 2C ligands. Sci World J 10:1870-1885
6. Bubar MJ, Cunningham KA (2008) Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. Prog Brain Res 172: 319-346, and references therein
7. Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53-61
8. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (2000) Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res 865:85-90 (Pubitemid 30256209)
9. Fletcher PJ, Lê AD, Higgins GA (2008) Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog Brain Res 172:361-83
10. Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD, Fletcher PJ (2012) The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology 37:1177-91
11. Manvich DF, Kimmel HL, Howell LL (2012) Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 341:424-34
12. Cai J, Yi Z, Lu W, Fang Y, Zhang C (2013) Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction. Med Hypotheses 80:486-9
13. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW(2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.Mol Pharmacol 57:75-81 (Pubitemid 30033262)
14. Hill MJ, Reynolds GP (2011) Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. Pharmacogenomics 12:727-34
15. Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ (2010) Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and metaanalysis. Pharmacogenomics 11:1561-71
16. Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, Arends J, Mulder H (2012) Association between HTR2C gene polymorphisms and themetabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J 12: 62-7
17. Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S, Del Favero J, Dikeos DG, Kaneva R, Lilli R, Massat I, Milanova V, Muir W, Noethen M, Oruc L, Petrova T, Papadimitriou GN, Rietschel M, Serretti A, Souery D, Van Gestel S, Van Broeckhoven C, Mendlewicz J (2001) Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 6:579-85 (Pubitemid 32772567)
18. Mickey BJ, Sanford BJ, Love TM, Shen PH, Hodgkinson CA, Stohler CS, Goldman D, Zubieta JK (2012) Striatal dopamine release and genetic variation of the serotonin 2C receptor in humans. J Neuroscience 32:9344-50
19. 2C receptor has as a cleavable signal peptide. Eur J Pharmacol 684: 44-50
20. Piva F, Giulietti M, Armeni T, Principato G (2012) Cross-link immunoprecipitation data to detect polymorphisms lying in splicing regulatory motifs: amethod to refine single nucleotide polymorphism selection in association studies. Psychiatr Genet 22:88-91
21. Piva F, Giulietti M, Baldelli L, Nardi B, Bellantuono C, Armeni T, Saccucci F, Principato G (2011) Bioinformatic analyses to select phenotype affecting polymorphisms in HTR2C gene. Hum Psychopharmacol 26:365-72
22. Piva F, Giulietti M, Nardi B, Bellantuono C, Principato G (2010) An improved in silico selection of phenotype affecting polymorphisms in SLC6A4, HTR1A and HTR2A genes. Hum Psychopharmacol 25: 153-61
23. Bray JK, Goddard WA III (2008) The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists. J Mol Graph Model 27:66-81
24. McRobb FM, Capuano B, Crosby IT, Chalmers DK, Yuriev E (2010) Homology modeling and docking evaluation of aminergic G protein-coupled receptors. J Chem Inf Model 50:626-637
25. Cordova-Sintjago T, Sakhuja R, Kondabolu K, Canal CE, Booth RG (2012) Molecular determinants for ligand binding at serotonin 5-HT2A and 5-HT2C GPCRs: experimental affinity results analyzed by molecular modeling and ligand docking studies. Int J Quantum Chem 112:3807-3814
26. Galeazzi R,Massaccesi L (2012) Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study. J Mol Model 18:1153-1166
27. Galeazzi R (2009) Molecular dynamics as a tools in Rational Drug Design: current status and some major applications. Current Comp Aid Mol Des 5:225-240
28. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi H-J, Kuhn P, Weis WI, Kobilka BK, Stevens RC (2007) High-resolution crystal structure of an engineered human β2-adrenergic G protein coupled receptor. Science 318:1258-1265 (Pubitemid 350172884)
29. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi H-J, Yao X-J, Weis WI, Stevens RC, Kobilka BK (2007) GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science 318:1266-1273 (Pubitemid 350172885)
30. Dong M, Lam PCH, Pinon DI, Abagyan R, Miller LJ (2009) Elucidation of the molecular basis of cholecystokinin peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling. Biochemistry 48:5303-5312
31. Keat YB, Buckle MJC, Doughty SW(2012) Homology modeling of the human 5-HT1A, 5-HT2A, D1, and D2 receptors: model refinement with molecular dynamics simulations and docking evaluation. J Mol Model 18:3639-3655
32. Kim SK, Li Y, Abrol R, Heo J, Goddard WA III (2011) Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors. J Chem Inf Model 51:420-433
33. Wacker D, Wang C, Katritch V, Won Han G, Huang XP, Vardy E, McCorvy JD, Jiang Y, Chu FM, Siu Y, Liu W, Xu HE, Cherezov V, Roth BL, Stevens RC (2013) Structural features for functional selectivity at serotonin receptors. Science (Washington, DC, United States) 340(6132):615-619
34. Suite 2011:MacroModel, version 9.9, Schrödinger, LLC, New York, NY, 2011
35. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM Jr, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA (1995) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117:5179-5197
36. Gilbert JC, Nocedal J (1992) Global Convergence Properties of Conjugate Gradient Methods for Optimization. SIAM J Optim 2: 21-42
37. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP (1985) Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 107:3902-3909
38. Rocha GB, Freire RO, Simas AM, Stewart JJ (2006) RM1: A reparameterization of AM1 for H C, N, O, P, S, F, Cl, Br, and I. J Comput Chem 27:1101-11
39. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) Molecular graphics and analyses were performed with the UCSF Chimera package. Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311). J Comput Chem 25:1605-12
40. Adzubei I, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) Nat Methods 7:248-249
41. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073-81
42. Ng PC, Henikoff S (2006) Predicting the Effects of Amino Acid Substitutions on Protein Function. Annu Rev Genomics Hum Genet 7:61-80 (Pubitemid 44627922)
43. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714-2723 (Pubitemid 28059943)
44. Morris GM, Huey R, Lindstrom W, SannerMF, Belew RK, Goodsell DS, Olson AJ (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Computational Chemistry 16:2785-91
45. Sanner MF, Duncan BS, Carrillo CJ, Olson AJ (1999) Pac Symp Biocomput 401-412
46. A.Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662
47. Hetényi C, van der Spoel D (2002) Protein Sci 11:1729-1737
48. den Otter WK, Briels WJ (1998) The calculation of free-energy differences by constrained molecular-dynamics simulations. J Chem Phys 109:4139-4147
49. Ewing TJA, Kuntz ID (1997) J Comput Chem 18:1175-1189
50. Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graphics 14:33-38 (Pubitemid 26152973)
51. Huey R, Morris GM, Olson AJ, Goodsell DSA (2007) Semiempirical free energy force field with charge-based desolvation. J Comput Chem 28:1145-1152 (Pubitemid 46506716)
52. Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS v.4.6.2.GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4:435-447
53. Guy AT, Piggot TJ, Khalid S (2012) Single-stranded DNA within nanopores: conformational dynamics and implications for sequencing; amolecular dynamics simulation study. Biophysical journal 103: 1028-1036
54. Jorgensen WL (1998) Temperature dependence of TIP3P, SPC, and TIP4P water from NPT Monte Carlo simulations: seeking temperatures of maximum density. J Computational Chemistry 19:1179-1186
55. Vohra S, Musgaard M, Bell SG, Wong LL, Zhou W, Biggin PC (2013) The dynamics of camphor in the cytochrome P450 CYP101D2. Protein Sci 22(9):1218-29
56. Münz M, Hein J, Biggin PC (2012) The role of flexibility and conformational selection in the binding promiscuity of PDZ domains. PLoS Comput Biol 8(11):e1002749
57. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103: 8577-8593
58. Isaac MT (2008) Treating depression with SNRIs: who will benefit most? CNS Spectr 13:15-21
59. Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J (1996) Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) 126:234-40 (Pubitemid 26252760)
60. Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295:226-32
61. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526
62. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880 (Pubitemid 34031892)
63. Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K (2000) Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse 35:144-150 (Pubitemid 30036191)
64. Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27:600-11 (Pubitemid 15010691)
65. Marwood JF, Stokes GS (1984) Studies on the mechanism of action of the hypotensive effect of ketanserin. Clin Exp Pharmacol Physiol 11(2):125-32 (Pubitemid 14101429)
66. Ashid M, Manivet P, Nishio H, Pratuangdejkul J, Rajab M, Ishiguro M, Launay JM, Nagatomo T (2003) Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci 73:193-207 (Pubitemid 36555937)
67. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, BickerdikeM(2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptor. Naunyn Schmiedebergs Arch Pharmacol 370:114-23 (Pubitemid 39222863)
68. Bonhaus DW,Weinhardt KK, TaylorM, DeSouza A,McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997) RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36: 621-9 (Pubitemid 27272107)
69. Harvey PJ, Li X, Li Y, Bennett DJ (2006) Endogenous monoamine receptor activation is essential for enabling persistent sodium currents and repetitive firing in rat spinal motoneurons. J Neurophysiol 96: 1171-86 (Pubitemid 44371512)
70. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, BickerdikeM(2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn Schmiedeberg's Arch Pharmacol 370:114-123 (Pubitemid 39222863)
71. Wang CD, Gallaher TK, Shih JC (1999) Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. Mol Pharmacol 43:931-940
72. Herrick-Davis K, Grinde E, Niswender CM(2002) Serotonin 5-HT2C receptor RNA editing alters receptor basal activity. J Neurochem 73: 1711-1717
73. Iorga B, Herlem D, Barré E, Guillou C (2006) Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach. J Mol Mod 12:366-372 (Pubitemid 43337207)
74. Hetényi C, Van der Spoel D (2002) Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci 11: 1729-1737 (Pubitemid 34663553)
75. Hetényi C, Van der Spoel D (2006) Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett 580:1447-1450 (Pubitemid 43222013)
76. Ciarkowski J, Witt M, Slusarz R (2005) A hypothesis for GPCR activation. J Mol Model 11:407-415 (Pubitemid 41644677)
77. Kobilka BK (2007) G protein coupled receptor structure and activation. Biochim Biophys Acta 1768:794-807
78. Cordova-Sintjago TC, Fang L, Bruysters M, Leurs R, Booth RG (2012) J Chem Pharm Res 4:2937-2951
79. Cordova-Sintjago TC, Villa N, Fang L, Booth RG (2013) Aromatic interactions impact ligand binding and function at serotonin 5-HT2C G protein-coupled receptors: receptor homology modelling, ligand docking, and molecular dynamics results validated by experimental studies. Mol Phys doi:10.1080/00268976.2013.833656
80. Brandl M, Weiss MS, Jabs A, Sühnel J, Hilgenfeld R (2001) C-H⋯pi-interactions in proteins. J Mol Biol 307:357-77
81. Plevin MJ, Bryce DL, Boisbouvier J (2010) Direct detection of CH/pi interactions in proteins. Nat Chem 2:466-71
82. Ballesteros JA, Weinstein H (1995) Integrated methods and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428
83. Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA (2008) Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Progress in neuro-psychopharmacology &biological psychiatry 32:1879-83
84. Pellissier LP, Sallander J, Campillo M, Gaven F, Queffeulou E, Pillot M, Dumuis A, Claeysen S, Bockaert J, Pardo L (2009) Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors. Mol Pharmacol 75:982-90
85. Dahl ACE, Chavent M, Sansom MSP (2012) Bendix Plugin in VMD. Bendix: intuitive helix geometry analysis and abstraction. Bioinformatics 28:2193-2194
86. Canal CE, Cordova-Sintjago TC, Villa NY, Fang LJ, Booth RG (2011) Drug discovery targeting human 5-HT2C receptors: Residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation. Eur J Pharm 673:1-12